In this study, we investigated the potential utility of cfDNA for the detection of BRAF mutation status in a large group of patients enrolled into the AZD6244 advanced melanoma phase II study to determine whether cfDNA mutations could be used for patient selection as an alternative to tissue biopsies. This evidence concerns the gene BRAF and melanoma.